ClinicalTrials.gg
CompletedNCT04601207Updated Mar 3, 2021

A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population

A Phase 1 interventional study of Cannabis Preparation and Cannabis Preparation in Healthy and Cannabis, sponsored by New Age Ventures LLC. Completed at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by New Age Ventures LLC · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of this study is to investigate the bioavailability of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) in an emulsion product against a comparator product. Thirty-two participants will be randomized into a single-center, double-blind, parallel trial. Participants will be dosed in clinic and blood and urine samples will be taken over a 12-hour period. Blood and urine samples will also be collected for 48 hours post-dose at check-in visits. Questionnaires regarding drug effects and cognitive function will also be completed following each blood sampling. Participants who consumed the comparator product will be asked to return to the clinic following a wash-out period of at least 45 days to consume the emulsion product in-clinic and complete questionnaires at the same specified time points over a 12-hour period.

Read the detailed description

The use of marijuana or cannabis for medicinal purposes is deeply rooted in history, and medicinal preparations from Cannabis indica and C. sativa have been used for almost 5,000 years for treating nausea, inflammation, vomiting and pain. However, the major lipophilic cannabinoids out of >60 terpenophenolic compounds that cause these effects were not identified until the early 20th century. Sativex, dronabinol, and nabilone (synthetic or similar to cannabinoids) are the only currently approved cannabis derived medicinal products in the United States and Canada for different conditions such as nausea and vomiting associated with cancer, multiple sclerosis, intractable cancer pain, etc. Controversies regarding legal, medicinal and ethical use of cannabis have increasingly placed this plant in the spotlight in recent years. Although the use of cannabis fell from favor to fear in the early 1900s, a widespread support for its use for medicinal purposes has been on the rise in several countries across the world.

Cannabidiol (CBD), a cannabinoid constituent of cannabis plants possesses anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties, without exhibiting the psychoactive effects of Δ9-tetrahydrocannabinol (Δ9-THC), the other major cannabinoid from the same plant Δ9-THC and CBD are biosynthesized as Δ9-tetrahydrocannabinolic acid and cannabidiolic acid from the common precursor olivetol. Both Δ9-THC and CBD exert their effects by interacting with the G protein-coupled cannabinoid receptors (GPCRs), CB1 and CB2 with varying affinities. While CB1 receptors are expressed in large quantities in the brain and regions central nervous system, and in lower amounts in peripheral tissues; the less studied CB2 receptors have been identified to be localized to immune cells, tonsils and the spleen. The CB1 receptors have been identified to play significant roles in pain perception, memory, motor regulation, appetite, mood, and sleep, whereas the CB2 receptors have been linked with anti-inflammation, pain reduction and reducing tissue damage. Physiologically, upon activation by the endocannabinoids like anandamide and 2-arachidonylglycerol (2-AG) (which are short lived), CB1 and CB2 trigger a downstream cascade of events that mediate homeostasis and healthy functioning. In contrast, the phytocannabinoids Δ9-THC and CBD that directly or indirectly interact with CB1 and CB2 with varying affinities modulate the activities of these receptors for prolonged durations.

Δ9-THC is the major psychoactive cannabinoid and mimics the action of the endogenous cannabinoid receptor ligands anandamide and 2-AG by activating both CB1 and CB2 receptors. Due to its binding to CB1 receptors which are specifically present in the central nervous system in areas associated with pain (eg. Spinal trigeminal nucleus, amygdala, basal ganglia and periaqueductal gray), Δ9-THC possesses antinociceptive activity and is hence used as an analgesic agent in certain pain medications. In addition, Δ9-THC has also been shown to be effective in the treatment of glaucoma, nausea, chronic pain, multiple sclerosis, epilepsy and inflammation in several pre-clinical and clinical studies . However, Δ9-THC abuse is a global concern and due to the behavioural and psychological dependence, Δ9-THC has remained a subject of controversy and a largely unproved therapy with limited studies establishing its benefit-to-risk ratio, safety and efficacy for different indications.

CBD, which is the non psychoactive phytocannabinoid, and can hence be a promising therapeutic has gained increasing attention in the recent past. Previous studies have shown that CBD is a promising potential therapeutic for various disorders of the central nervous system including anxiety, epilepsy, schizophrenia, Parkinson's disease, Alzhiemer's disease, multiple sclerosis and many more. Unlike Δ9-THC, CBD does not activate CB1 and CB2, and instead blocks the cannabinoids that activate these receptors by a complex mechanism. Several groups have proposed that this activity not only results in the non-psychotropic effects exhibited by CBD but may also account for ameliorating some of the psychotropic effects shown by Δ9-THC. In addition, by lowering the psychoactivity of Δ9-THC, CBD may also potentiate some of Δ9-THC's benefits by enhancing its tolerability and widening its therapeutic window. CBD can also inhibit or delay the reuptake and hydrolysis of the endocannabinoids like anandamide and adenosine. CBD has also been hypothesized to interact with several other non-endocannabinoid signaling systems such as serotonin receptors, vanilloid receptors, GPR-55 (orphan receptors), peroxisome proliferator activated receptors (PPARs) making it a "multi-target drug". In addition to these activities, the polyphenolic ring in CBD also results in it being a potent antioxidant. All these results have prompted the exploration of the therapeutic potential of CBD for a range of neuropsychiatric as well as inflammatory disorders.

Several groups have attempted to study the pharmacokinetics and pharmacodynamics of CBD and Δ9-THC. It is generally accepted in drug research that lipophilicity promotes the passage of molecules across cellular barriers and therefore the most lipophilic compounds will have greatest intestinal absorption. Due to the lipophilicity of cannabinoids, smoking results in the fastest absorption of CBD and Δ9-THC, however, the half-life of CBD in humans was found to be between 18-33 h upon intravenous injection, 27-35 h upon smoking, and 2-5 days upon oral administration. Bioavailability of oral and smoked CBD in humans was found to be around 6% and 31%, respectively; and bioavailability of oral and smoked Δ9-THC is shown to be 4-12% and 10-27% respectively. Other studies have previously determined the time to achieve peak plasma concentration (tmax) as 1.5- 4 h for different doses of CBD and 1-2 h for different doses of Δ9-THC. This single-center, randomized, double-blind, comparator-controlled, parallel study will investigate the bioavailability of CBD and Δ9-THC in the test product- SolutechTM - TC10 manufactured by New Age Ventures LLC in a healthy population.

02

Conditions studied

  • Healthy
  • Cannabis

Keywords

  • Cannabis
  • THC
  • CBD
  • Healthy Adult
03

In context

Lead sponsor

This is the only study on the registry with New Age Ventures LLC as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide voluntary, written to participate in the study
  2. Between 18 and 45 years of age at screening
  3. Occasional users of Cannabis: Have consumed cannabis product at least once in the past 6 months and at least 4 times in their lifetime and have experienced psychotropic effects without severe adverse events (short term paranoia, belligerence, extreme hallucinations) requiring medical interventions. Eligibility will be determined on a case by case basis by the QI.
  4. Must agree to a 30-day washout of cannabis products prior to baseline.
  5. Willingness to complete questionnaires, records and diaries associated with the study
  6. Have a (BMI) in the range of 19.0 to 29.9 kg/m2 at baseline
  7. Be willing to provide blood over a 12 h period via an Intravenous (IV) catheter
  8. Blood pressure at screening does not exceed a systolic blood pressure (SBP) of 140 mmHg and a diastolic blood pressure (DBP) of 90 mmHg
  9. Agree to refrain from smoking tobacco products, including e-cigarettes and vaporizers or consume alcohol 24 hrs prior to their baseline visit and until completion of the study period.
  10. Men who are able to father children must agree to use medically acceptable methods of during the study and for 30 days after the end of the study and report any pregnancies. If a subject's partner becomes pregnant during his participation in the study or within 30 days after he has completed his last drug administration, he must inform the QI immediately
  11. Female participant is not of child bearing potential, which is defined as females who have had a hysterectomy or bilateral oophorectomy, bilateral tubal ligation or natural menopause (have not had menses for > 1 year, as confirmed by measurement of serum FSH ≥ 40 IU/L at screening visit) Or,

    Females of must agree to abstain from heterosexual intercourse or use two methods of contraception for 30 days prior to first treatment and for 30 days after the last treatment. Subjects must have a negative urine pregnancy test result at screening, baseline and visit 5. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6- months prior to screening (Female subjects whose partners who have had a vasectomy must verbally confirm that their partner's vasectomy was confirmed to be successful by previous assessment of semen samples)
  12. Agree not to donate blood within 30 days after visit 2, visit 3, visit 4 and visit 5
  13. Agrees to refrain from consuming supplements in section 5.3.2 during the study
  14. Agrees not to drive or operate heavy machinery if feeling dizzy or drowsy following drug administration until full mental alertness is regained after treatment visits
  15. Agrees to provide information of two adult contacts to be reached in the event of transportation requirements from the clinic to their home after the study visits
  16. Healthy as determined by the following criteria: laboratory results, medical history, physical exam, meeting all the inclusion criteria, not meeting any of the exclusion criteria and not on any concomitant medications listed in Section 5.3. Eligibility will be assessed by the QI based on the above.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant, breast feeding, or planning to become pregnant during the trial
  2. abnormal laboratory results at screening as determined by the QI.
  3. Verbal confirmation of hepatic or pancreatic malfunctions
  4. Verbal confirmation of use of medicinal or recreational products containing CBD/THC in the past 1 month, for participants that have consumed CBD or THC containing products prior to 1 month, eligibility will be assessed by the QI on a case by case basis depending on frequency and amount.
  5. Verbal confirmation of use of hemp seeds or hemp oil in the past 1 month, for participants that have consumed hemp seeds or hemp oil prior to 1 month, eligibility will be assessed by the QI on a case by case basis depending on frequency and amount.
  6. Verbal confirmation of habitual use of cannabis for medical or recreational purposes: >4 times a month. For participants who have consumed cannabis products ≤4 times a month, eligibility will be assessed by the QI depending on dose and frequency of use and self reported adverse events
  7. Tongue piercings and/or mouth jewelry
  8. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable after an assessment by QI
  9. History (within the past 5 years) of or current Fourth Edition (DSM-IV) diagnosis of substance dependence. For participants who have a history of substance dependence greater than 5 years ago, eligibility will be assessed on a case by case basis by the QI.
  10. Currently seeking or participating in treatment for substance-related disorders
  11. History of participation in treatment for substance-related disorders, including successful completion of such treatment within the past 5 years. For participants who have a sought treatment for substance abuse greater than 5 years ago, eligibility will be assessed on a case by case basis by the QI.
  12. Clinically significant history of or presence of any clinically significant oral or gastrointestinal pathology (e.g. mouth ulcers, chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug experienced within 7 days prior to baseline (visit 2) and visit 5.
  13. Use of prescribed or over the counter medication which in the opinion of QI will interfere with study results or safety of the subject. Please refer to Section 5.3.1 and 5.3.2.
  14. Verbal confirmation of current or history of bleeding disorders. Will be assessed by QI on a case by case basis depending on the disorder
  15. Participation in a clinical research trial within 30 days prior to randomization
  16. Allergy or sensitivity to product and MCT-diluted cannabis oil ingredients
  17. Verbal confirmation of diabetes and use of diabetes medication. However, eligibility will be assessed by the QI on a case by case basis based on dose and frequency of medication.
  18. Current or previous history of clinically diagnosed neuropsychiatric disorders as per qualified investigator's (QI) opinion
  19. Presence of drugs: amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), nicotine (cotinine), alcohol and THC and metabolites in urine, at screening, baseline and visit 5 (if visit 5 is applicable).
  20. Personal or family history (immediate family) of psychosis: including schizophrenia and affective psychosis
  21. History of suicidal ideation attempts and/or behaviour
  22. Individuals who are cognitively impaired and/or who are unable to give 23. Verbal confirmation of any disease or immune-compromised (i.e. use of anti-rejection medication, rheumatoid arthritis,)
  1. Positive laboratory results for , or C as assessed at screening.
  1. Any current or recent active and unstable medical condition that could potentially affect the study objective or adversely affect the participant's ability to complete the study or safety of the subject as per the QI
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Solutech™- TC10

    10.0mg THC, 12.2 mg CBD liquid emulsion product given orally once in-clinic

    Drug: Cannabis Preparation

  • Active comparator
    MCT-diluted Cannabis Product

    10.0mg THC, 12.2 mg CBD liquid MCT-diluted oil product given orally once in-clinic

    Drug: Cannabis Preparation

Interventions

  • DrugCannabis Preparation

    Dosed as a single oral dose

    Also known as: Cannabis emulsion

  • Dosed as a single oral dose

    Also known as: Cannabis oil

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC0-48h)

    Area under the curve (AUC0-48h) for CBD, Δ9-THC, 11-OH-THC and 11-NOR-9-CARBOXY-Δ9-THC in plasma after the administration of the investigational product or active comparator product.

    Time frame: 48 hours (Time points assessed for AUC0-48 h: pre-dose and post-dose at 10, 20, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 and 48 hours)

  2. Maximum concentration (Cmax, 0-48h)

    Maximum concentration (Cmax, 0-48h) for CBD, Δ9-THC, 11-OH-THC and 11-NOR-9-CARBOXY-Δ9-THC in plasma after the administration of the investigational product or active comparator product.

    Time frame: 48 hours (Time points assessed for AUC0-48 h: pre-dose and post-dose at 10, 20, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 and 48 hours)

  3. Time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax, 0-48h) for CBD, Δ9-THC, 11-OH-THC and 11-NOR-9-CARBOXY-Δ9-THC in plasma after the administration of the investigational product or active comparator product.

    Time frame: 48 hours (Time points assessed for AUC0-48 h: pre-dose and post-dose at 10, 20, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 and 48 hours)

Secondary outcomes

  1. Urine CBD concentration

    CBD concentrations in urine after the acute administration of the investigational product and the active comparator product

    Time frame: 48 hours (Time points assessed are:0 (pre-dose), 0-4, 4-8, 8-12 hours, 12-24 hours and 24-48 hours post-dose)

  2. Urine Δ9-THC concentration

    Δ9-THC concentrations in urine after the acute administration of the investigational product and the active comparator product

    Time frame: 48 hours (Time points assessed are:0 (pre-dose), 0-4, 4-8, 8-12 hours, 12-24 hours and 24-48 hours post-dose)

  3. Cognitive function

    Assessment of cognitive functions by BrainCheck questionnaire for the investigational product and active comparator product. It involves tests of memory (immediate- and delayed-recall) and of cognitive processing and executive function (digit-symbol substitution, trail-making, Stroop Interference). Once a patient has completed the assessments, the BrainCheck platform immediately provides validated, norm-based scores to the investigators. These scores are adjusted for age, derived from a normative database ranging from ages 10 to 99. Raw scores for the different parameters are scaled and ranked in percentiles. Scores that fall within a range of one standard deviation above the mean (50th percentile) indicate "normal" cognitive function. So, overall scores above 50th percentile are graded normal cognitive function while those below 50th suggest cognitive impairment.

    Time frame: 48 hours

  4. Subjective evaluation of drug effects

    This is done using the Drug-effect questionnaire (DEQ-5) which is a 5-question questionnaire evaluating the effects of the study product. The Five questions assess drug effects, perception and likability. The number and percentage of subjects per response will be presented for each time point according to treatment. Differences between groups will be assessed using a generalized linear mixed model assuming an ordinal response with treatment, time points and treatment by time points as fixed effects and subject as random effect.Outcomes will be summarized using descriptive statistics.

    Time frame: 48 hours

Other outcomes

  1. Pre-emergent and post-emergent adverse events

    The incidence of pre-emergent and post-emergent adverse events following a single dose of the investigational product and the comparator product. Adverse events are recorded in the study diary.

    Time frame: 72 hours

  2. Blood pressure

    The effect of a single dose of the investigational product and the comparator product on systolic and diastolic blood pressure

    Time frame: 48 hours post dose

  3. Heart rate

    The effect of a single dose of the investigational product and the comparator product on heart rate

    Time frame: 48 hours post dose

  4. Alanine aminotransferase (ALT)

    The effect of a single dose of the investigational product and the comparator product on alanine aminotransferase (ALT)

    Time frame: 48 hours post dose

  5. Aspartate aminotransferase (AST)

    The effect of a single dose of the investigational product and the comparator product on aspartate aminotransferase (AST)

    Time frame: 48 hours post dose

  6. Bilirubin

    The effect of a single dose of the investigational product and the comparator product on bilirubin

    Time frame: 48 hours post dose

  7. Creatinine

    The effect of a single dose of the investigational product and the comparator product on creatinine

    Time frame: 48 hours post dose

  8. Sodium ion

    The effect of a single dose of the investigational product and the comparator product on sodium ion

    Time frame: 48 hours post dose

  9. Potassium ion

    The effect of a single dose of the investigational product and the comparator product on potassium ion

    Time frame: 48 hours post dose

  10. Chloride ion

    The effect of a single dose of the investigational product and the comparator product on chloride ion

    Time frame: 48 hours post dose

  11. Calcium ion

    The effect of a single dose of the investigational product and the comparator product on calcium ion

    Time frame: 48 hours post dose

  12. Estimated glomerular filtration rate (eGFR)

    The effect of a single dose of the investigational product and the comparator product on estimated glomerular filtration rate (eGFR)

    Time frame: 48 hours post dose

  13. White blood cell count

    The effect of a single dose of the investigational product and the comparator product on white blood cell count

    Time frame: 48 hours post dose

  14. Neutrophils

    The effect of a single dose of the investigational product and the comparator product on neutrophils

    Time frame: 48 hours post dose

  15. Lymphocytes

    The effect of a single dose of the investigational product and the comparator product on lymphocytes

    Time frame: 48 hours post dose

  16. Monocytes

    The effect of a single dose of the investigational product and the comparator product on monocytes

    Time frame: 48 hours post dose

  17. Eosinophils

    The effect of a single dose of the investigational product and the comparator product on eosinophils

    Time frame: 48 hours post dose

  18. Basophils

    The effect of a single dose of the investigational product and the comparator product on basophils

    Time frame: 48 hours post dose

  19. Red blood cell count

    The effect of a single dose of the investigational product and the comparator product on red blood cell count

    Time frame: 48 hours post dose

  20. Hemoglobin

    The effect of a single dose of the investigational product and the comparator product on hemoglobin

    Time frame: 48 hours post dose

  21. Hematocrit

    The effect of a single dose of the investigational product and the comparator product on hematocrit

    Time frame: 48 hours post dose

  22. Platelet count

    The effect of a single dose of the investigational product and the comparator product on platelet count

    Time frame: 48 hours post dose

  23. The effect of a single dose of the investigational product and the comparator product on Mean corpuscular volume (MCV)

    Mean corpuscular volume (MCV)

    Time frame: 48 hours post dose

  24. Mean corpuscular hemoglobin (MCH)

    The effect of a single dose of the investigational product and the comparator product on mean corpuscular hemoglobin (MCH)

    Time frame: 48 hours post dose

  25. Mean corpuscular hemoglobin concentration (MCHC)

    The effect of a single dose of the investigational product and the comparator product on mean corpuscular hemoglobin concentration (MCHC)

    Time frame: 48 hours post dose

  26. Red cell distribution width (RDW)

    The effect of a single dose of the investigational product and the comparator product on red cell distribution width (RDW)

    Time frame: 48 hours post dose

07

Study locations

1 site
  • KGK Science Inc.
    London, Ontario N6A 5R8, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Nov 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2020
First posted
Oct 23, 2020
StartActual
Jun 19, 2020
Primary completionActual
Nov 30, 2020
CompletionActual
Nov 30, 2020
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04601207
Lead sponsor
New Age Ventures LLC
Collaborators
KGK Science Inc.
Responsible party
Sponsor
First posted
Oct 23, 2020
Start date
Jun 19, 2020
Primary completion
Nov 30, 2020
Completion
Nov 30, 2020
Last update
Mar 3, 2021

Study contacts

David Crowley, MD
principal investigator · KGK Science Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa flowering TOP

Start the discussion